AIclinicalresearch/backend/scripts/test-results/test-results-2025-11-18T08-10-57-407Z.json

{
  "metrics": {
    "totalTests": 10,
    "correctDecisions": 6,
    "accuracy": 0.6,
    "consistencyRate": 0.7,
    "jsonValidRate": 1,
    "avgConfidence": 0.9475,
    "needReviewRate": 0.3,
    "confusionMatrix": {
      "truePositive": 2,
      "falsePositive": 0,
      "trueNegative": 4,
      "falseNegative": 1,
      "uncertain": 0
    }
  },
  "results": [
    {
      "literatureId": "test-001",
      "title": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial",
      "expectedDecision": "include",
      "actualDecision": "exclude",
      "isCorrect": false,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.925,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "we randomly assigned 800 adults with type 2 diabetes",
          "I": "We evaluated the efficacy and safety of empagliflozin in patients with type 2 diabetes",
          "C": "placebo-controlled trial",
          "S": "randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "exclude",
        "confidence": 0.9,
        "reason": "虽然该文献在PICO标准方面完全匹配（P：2型糖尿病成人患者；I：SGLT2抑制剂empagliflozin；C：安慰剂对照；S：随机对照试验），且满足纳入标准中的研究设计、干预措施、语言和时间要求，但文献明确缺乏心血管结局数据。摘要中仅报告了血糖控制（HbA1c变化）、体重、血压和不良事件等次要终点，未提及主要不良心血管事件、心衰住院或心血管死亡等心血管结局指标。根据研究方案要求，文献必须报告心血管结局数据才能纳入，因此予以排除。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "patients with type 2 diabetes and inadequate glycemic control (HbA1c 7.0-10.0%)",
          "I": "to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily",
          "C": "placebo once daily",
          "S": "randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "尽管该研究符合PICO中的P、I、C、S标准，人群为成人2型糖尿病患者，干预为SGLT2抑制剂（empagliflozin），对照为安慰剂，设计为RCT，但未报告方案所要求的心血管结局指标（如MACE、心衰住院、心血管死亡）。摘要中提及的结局为HbA1c、体重、血压和不良事件，无心血管相关终点数据，因此不满足纳入标准第4条“报告心血管结局数据”，故排除。"
      },
      "processingTime": 11935
    },
    {
      "literatureId": "test-002",
      "title": "Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes",
      "expectedDecision": "include",
      "actualDecision": "include",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "We randomly assigned 8246 patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
          "I": "ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor",
          "C": "ertugliflozin (5 mg or 15 mg) or placebo, in addition to standard care",
          "S": "We randomly assigned 8246 patients...The primary outcome was major adverse cardiovascular events"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该文献完全符合纳入标准：研究对象为2型糖尿病成人患者（≥18岁），干预措施为SGLT2抑制剂（ertugliflozin），对照为安慰剂加标准治疗，研究设计为随机对照试验，报告了心血管结局数据（主要不良心血管事件和心衰住院），发表于2010年后且为英文文献。同时，该文献未触发任何排除标准，不是综述、病例报告、动物实验、会议摘要或观察性研究。因此明确纳入。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
          "I": "ertugliflozin (5 mg or 15 mg)",
          "C": "placebo, in addition to standard care",
          "S": "We randomly assigned 8246 patients... to receive ertugliflozin (5 mg or 15 mg) or placebo"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该研究纳入2型糖尿病成人患者，符合P标准；干预措施为SGLT2抑制剂ertugliflozin，符合I标准；对照为安慰剂，符合C标准；研究设计为随机对照试验，符合S标准。研究明确报告了主要不良心血管事件、心衰住院等结局，满足O维度要求。文献为英文RCT，发表于2010年后，非综述或观察性研究，完全符合所有纳入标准且未触发任何排除标准，因此决定纳入。"
      },
      "processingTime": 13225
    },
    {
      "literatureId": "test-003",
      "title": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "in adults with type 2 diabetes",
          "I": "SGLT2 inhibitors",
          "C": "comparing SGLT2 inhibitors with placebo or active comparators",
          "S": "Systematic Review and Meta-Analysis"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "这篇文献明确触发排除标准第1条（综述、系统评价、Meta分析），因为标题和摘要都明确表明这是一篇系统综述和Meta分析，而非原始随机对照试验。虽然研究人群（2型糖尿病成人患者）、干预措施（SGLT2抑制剂）和对照（安慰剂或活性对照）都符合PICO标准，但研究设计类型不符合要求的RCT设计。根据排除标准，所有综述、系统评价和Meta分析都应被排除，因此直接排除此文献。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
          "I": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
          "C": "comparing SGLT2 inhibitors with placebo or active comparators",
          "S": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献为系统评价和Meta分析，研究设计不符合方案要求的原始随机对照试验（RCT），因此排除。尽管其纳入的研究可能符合PICO标准，但本文本身并非原始研究，不提供独立的实证数据。P、I、O均匹配或部分匹配，但S明确不匹配。根据排除标准第1条，系统评价和Meta分析应被排除。"
      },
      "processingTime": 10683
    },
    {
      "literatureId": "test-004",
      "title": "Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "mismatch",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection",
          "I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day)",
          "C": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks",
          "S": "We investigated the effects of dapagliflozin on cardiac function in diabetic rats"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确不符合纳入标准，应予以排除。主要理由包括：(1)研究对象为糖尿病大鼠而非人类2型糖尿病患者，与PICO标准中'2型糖尿病成人患者'完全不匹配；(2)研究设计为动物实验而非随机对照试验，触发排除标准第3条；(3)虽然干预措施为SGLT2抑制剂(dapagliflozin)且设置了对照(vehicle)，但研究对象和研究设计的根本性不匹配决定了必须排除。这是一项基础医学研究，不符合系统综述关注临床证据的要求。"
      },
      "qwenResult": {
        "judgment": {
          "P": "mismatch",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection.",
          "I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
          "C": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
          "S": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究使用糖尿病大鼠模型，研究人群不符合成人2型糖尿病患者的要求，属于动物实验，明确违反纳入标准并触发排除标准3。尽管干预措施为dapagliflozin且采用随机设计，但研究对象非人类，无法外推至目标人群。研究设计虽提及随机分配，但整体为动物实验，不属于RCT临床试验。因此，该文献应排除。"
      },
      "processingTime": 13067
    },
    {
      "literatureId": "test-005",
      "title": "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
      "expectedDecision": "include",
      "actualDecision": "include",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "participants with type 2 diabetes and albuminuric chronic kidney disease",
          "I": "receive canagliflozin at a dose of 100 mg daily",
          "C": "or placebo",
          "S": "In this double-blind trial, we randomly assigned 4401 participants"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该文献完全符合纳入标准：研究对象为2型糖尿病成人患者，干预措施为SGLT2抑制剂canagliflozin，对照为安慰剂，研究设计为随机对照试验。虽然摘要主要关注肾脏结局，但明确提到'cardiovascular events'作为复合终点的一部分，且'death from renal or cardiovascular causes'包含心血管死亡结局。研究发表于2010年后，为英文文献，完全符合所有PICO标准和纳入标准，无任何排除标准触发。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "participants with type 2 diabetes and albuminuric chronic kidney disease",
          "I": "canagliflozin at a dose of 100 mg daily",
          "C": "placebo",
          "S": "In this double-blind trial, we randomly assigned 4401 participants...to receive canagliflozin...or placebo"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该研究纳入2型糖尿病成人患者，使用SGLT2抑制剂（canagliflozin）作为干预，对照为安慰剂，研究设计为随机对照试验（RCT），符合PICO标准。摘要明确报告了心血管事件作为复合结局的一部分（'death from renal or cardiovascular causes'），满足心血管结局的纳入要求。研究发表于2018年（NEJM），英文全文，非综述或观察性研究，完全符合所有纳入标准且未触发任何排除标准，因此应纳入。"
      },
      "processingTime": 12352
    },
    {
      "literatureId": "test-006",
      "title": "Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "\"12,543 adults with type 2 diabetes\"",
          "I": "\"patients with type 2 diabetes who initiated SGLT2 inhibitor therapy\"",
          "C": "摘要中未提及安慰剂或常规降糖疗法作为对照",
          "S": "\"We conducted a retrospective cohort study\""
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确触发排除标准，应予以排除。虽然研究人群(P)为2型糖尿病成人患者，干预措施(I)为SGLT2抑制剂，符合纳入标准，但研究设计(S)为回顾性队列研究，明确不符合方案要求的随机对照试验(RCT)，且摘要中未提及任何对照措施(C)。此外，该研究主要关注血糖控制、体重变化和安全性结局，而非方案要求的心血管结局。根据排除标准第7条，观察性研究（包括队列研究）应被排除。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
          "I": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
          "C": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system.",
          "S": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究为回顾性队列研究，不符合方案要求的随机对照试验（RCT）设计，故S维度不匹配。虽然研究人群为成人2型糖尿病患者，且干预措施为SGLT2抑制剂，符合P和I标准，但对照组未明确为安慰剂或常规降糖疗法，C维度不匹配。此外，研究设计属于观察性研究，直接触发排除标准第7条，因此应排除。"
      },
      "processingTime": 11690
    },
    {
      "literatureId": "test-007",
      "title": "Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers",
      "expectedDecision": "exclude",
      "actualDecision": "pending",
      "isCorrect": false,
      "hasConsensus": false,
      "needReview": true,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "mismatch",
          "I": "partial",
          "C": "match",
          "S": "partial"
        },
        "evidence": {
          "P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers",
          "I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner",
          "C": "placebo-controlled",
          "S": "In this Phase 1 study...in a randomized, placebo-controlled, double-blind manner"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献应被排除，主要原因为：研究人群明确为健康志愿者而非2型糖尿病患者（P不匹配），这直接违反了纳入标准第1条和排除标准第5条。虽然研究涉及SGLT2抑制剂empagliflozin（I部分匹配）并采用安慰剂对照（C匹配），但研究设计为I期临床试验而非典型的RCT（S部分匹配），且未报告任何心血管结局数据。此外，研究关注的是药代动力学和药效学参数，与研究方案要求的心血管结局完全不符。基于研究人群不符合PICO标准且触发排除标准，决定排除该文献。"
      },
      "qwenResult": {
        "judgment": {
          "P": "mismatch",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers.",
          "I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
          "C": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
          "S": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究纳入的是健康志愿者，而非2型糖尿病患者，不符合P（研究人群）标准。尽管研究设计为RCT，干预措施为SGLT2抑制剂，对照为安慰剂，且发表于英文期刊，但P的不匹配直接触发排除标准第5条（健康志愿者研究）。因此，尽管其他PICO要素部分符合，仍应排除。"
      },
      "processingTime": 14253
    },
    {
      "literatureId": "test-008",
      "title": "Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes",
      "expectedDecision": "exclude",
      "actualDecision": "pending",
      "isCorrect": false,
      "hasConsensus": false,
      "needReview": true,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "Medicare beneficiaries aged ≥65 years with type 2 diabetes",
          "I": "patients initiating SGLT2 inhibitors (n=42,371)",
          "C": "compared with those initiating DPP-4 inhibitors (n=126,806)",
          "S": "We conducted a nationwide cohort study using claims data"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确触发排除标准，主要问题在于研究设计不符合要求。文献明确描述为队列研究（nationwide cohort study using claims data），而研究方案要求必须是随机对照试验（RCT）。对照措施部分匹配，虽然使用了DPP-4抑制剂作为对照，但研究方案要求安慰剂或常规降糖疗法。研究人群（老年2型糖尿病患者）和干预措施（SGLT2抑制剂）符合要求，结局指标也报告了心血管结局（心衰住院、主要不良心血管事件）。但由于研究设计为观察性队列研究，明确触发排除标准第7条，因此必须排除。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries aged ≥65 years with type 2 diabetes.",
          "I": "We compared patients initiating SGLT2 inhibitors (n=42,371) with those initiating DPP-4 inhibitors (n=126,806) between 2013 and 2017.",
          "C": "those initiating DPP-4 inhibitors",
          "S": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究纳入的是2型糖尿病患者，符合P标准；干预措施为SGLT2抑制剂，符合I标准。但对照组为DPP-4抑制剂，不符合方案中‘安慰剂或常规降糖疗法’的C标准，属于非等效对照。更重要的是，研究设计为队列研究，属于观察性研究，不满足S要求的随机对照试验（RCT），明确触发排除标准中的‘观察性研究’条款。因此，尽管部分PICO要素匹配，但因研究设计不符，应排除。"
      },
      "processingTime": 12808
    },
    {
      "literatureId": "test-009",
      "title": "Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "\"A 52-year-old man with type 2 diabetes\"",
          "I": "\"patient treated with dapagliflozin\"",
          "C": "摘要中未提及任何对照措施或安慰剂",
          "S": "\"We report a case of severe euglycemic diabetic ketoacidosis\"，明确为病例报告"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确触发排除标准：这是一篇病例报告（标题和摘要中多次提及'case report'和'case'），而非随机对照试验。虽然研究人群（2型糖尿病患者）和干预措施（SGLT2抑制剂）符合PICO标准，但研究设计不符合要求的RCT设计，且未报告心血管结局数据（主要讨论糖尿病酮症酸中毒）。根据排除标准第2条（病例报告、病例系列），应直接排除。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
          "I": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
          "C": "There is no mention of a control group or comparison with placebo or conventional therapy.",
          "S": "This is a case report, as indicated by the title: 'Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report'."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献为病例报告，研究设计不符合方案要求的随机对照试验（RCT），故S维度不匹配。尽管研究人群（P）和干预措施（I）符合标准，但缺乏对照组（C），且研究类型属于排除标准中的'病例报告'。根据排除标准第2条，此类文献应被排除。虽然提到了2型糖尿病患者使用SGLT2抑制剂，但无对照、非RCT设计，无法提供因果推断证据，因此最终决定排除。"
      },
      "processingTime": 12092
    },
    {
      "literatureId": "test-010",
      "title": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment",
      "expectedDecision": "uncertain",
      "actualDecision": "pending",
      "isCorrect": false,
      "hasConsensus": false,
      "needReview": true,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "mismatch",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "we enrolled 10,584 patients with type 2 diabetes",
          "I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor",
          "C": "randomly assigned to receive sotagliflozin 200 mg or placebo",
          "S": "In this randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确触发排除标准，主要问题在于干预措施不匹配。研究使用的是sotagliflozin（一种SGLT1和SGLT2双重抑制剂），而非方案要求的SGLT2抑制剂（如empagliflozin、dapagliflozin、canagliflozin等）。虽然研究人群（2型糖尿病成人患者）、对照（安慰剂）、研究设计（RCT）和结局指标（心血管结局）均符合PICO标准，且满足纳入标准中的研究设计、结局报告、语言和发表时间要求，但干预措施的根本性差异导致必须排除。SGLT1/SGLT2双重抑制剂与纯SGLT2抑制剂在作用机制和临床效果上存在差异，不应混为一谈。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "patients with type 2 diabetes, cardiovascular disease, and an estimated glomerular filtration rate of 25 to 60 ml per minute per 1.73 m²",
          "I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor... patients were randomly assigned to receive sotagliflozin 200 mg or placebo once daily",
          "C": "placebo once daily",
          "S": "randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该研究纳入2型糖尿病成人患者，符合P标准；干预措施为SGLT2抑制剂（sotagliflozin），虽为双抑制剂但包含SGLT2抑制作用，符合I标准；对照为安慰剂，符合C标准；研究设计为RCT，符合S标准。心血管结局明确报告了心血管死亡、心衰住院等复合终点，满足O指标要求。研究发表于2019年（基于背景知识），英文全文，非排除类型，完全符合所有纳入标准且未触发任何排除标准。"
      },
      "processingTime": 13503
    }
  ]
}